HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 901–1,000 of 1,000
Single-cell analysis of myeloid cells in HPV+ tonsillar cancer
Jimenez, D. G., Altunbulakli, C., Swoboda, S., Sobti, A., Askmyr, D., Ali, A., Greiff, L., & Lindstedt, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1087843 · Cited by 9
Monocytic myeloid‐derived suppressor cells regulate T‐cell responses against vaccinia virus
Fortin, C. F., Yang, Y., & Huang, X. (2017) · European Journal of Immunology · doi:10.1002/eji.201646797 · Cited by 8
Jang, T. J., Kim, S. A., & Kim, M.-K. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.06.016 · Cited by 9
Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?
Vitale, M., & Parodi, M. (2021) · Vaccines · doi:10.3390/vaccines9101144 · Cited by 9
Deng, X., Chen, X., Luo, Y., Que, J., & Chen, L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1202454 · Cited by 8
Flati, I., Nolfi, M. D. V., Dall’Aglio, F., Vecchiotti, D., Verzella, D., Alesse, E., Capece, D., & Zazzeroni, F. (2023) · Genes · doi:10.3390/genes14101953 · Cited by 8
Mastrogiovanni, M., Donnadieu, E., Pathak, R., & Bartolo, V. D. (2024) · Biology · doi:10.3390/biology13110860 · Cited by 10
Myeloid cells are involved in tumor immunity, metastasis and metabolism in tumor microenvironment
Zhang, C., Song, Y., Yang, H., & Wu, K. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10012-y · Cited by 9
Pan-Cancer Single-Cell RNA Sequencing Analysis Refines Multi-Origin Monocyte and Macrophage Lineages
Nguyen, T. D. T., Lee, A., Park, H. J., Shah, N., Mandzhieva, B., Lee, D., Jung, I., & Park, W. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1255 · Cited by 14
Munansangu, B. S. M., Kenyon, C. P., Walzl, G., Loxton, A. G., Kotzé, L. A., & du Plessis, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073512 · Cited by 10
Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity
Kim, H., Lee, E., Cho, H., Kim, E., Jang, W. I., Yang, K., Lee, Y., Kim, T., & Kim, M.-S. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.09.014 · Cited by 8
Self-citationTan, D. B. A., Fernández, S., Price, P., & Moodley, Y. P. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.09.011 · Cited by 7
Dziobek, K., Opławski, M., Grabarek, B. O., Zmarzły, N., Kieszkowski, P., Januszyk, P., Kiełbasiński, K., Kiełbasiński, R., & Boroń, D. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190911113611 · Cited by 7
Zhang, C., Li, H., Zhang, R., Ren, Z., & Wu, Y. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00380 · Cited by 7
Origin, production and molecular determinants of macrophages for their therapeutic targeting
Chowdhury, S., & Trivedi, A. K. (2022) · Cell Biology International · doi:10.1002/cbin.11914 · Cited by 9
Hong, Y., Xia, Z., Sun, Y., Lan, Y., Di, T., Yang, J., Sun, J. P., Qiu, M., Luo, Q., & Yang, D. (2023) · Genes · doi:10.3390/genes14040889 · Cited by 7
Inhibition of Hypoxia Inducible Factor 1α by siRNA‐Induced Apoptosis in Human Retinoblastoma Cells
Gao, Y., Ming, J., Ge, R., Zhou, Z., & Sun, Y. (2014) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21576 · Cited by 7
Andersson, P., & Ostheimer, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02083 · Cited by 9
Neutrophil PAD4: how does it function in cancer beyond promoting NETosis?
Garcia-Gerique, L., & Nefedova, Y. (2023) · Oncotarget · doi:10.18632/oncotarget.28369 · Cited by 8
Myeloid-Derived Suppressor Cells: Implications in Cancer Immunology and Immunotherapy
Santibanez, J. F. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25203 · Cited by 9
Kah, G., & Abrahamse, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633953 · Cited by 9
Bahng, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1713123 · Cited by 6
Dong, Z., Dai, H., Zhang, X., Zhao, Z., Chen, Y., Zheng, Y., Rui, H., Liu, B., & Zhong, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772536 · Cited by 10
The hallmarks of pancreatic cancer
Kane, L. E., Hackett, D., Lyons, R. G., Ryan, B. M., & Maher, S. G. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218437 · Cited by 9
Lactate and lactylation: mechanisms, function, diseases, and therapeutic targets
Wang, X., Liu, C., Chen, Y., Fang, Y., Li, J. N., Liu, Y., Pan, Y., Bao, S., Wang, X., Liu, Y., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00472-x · Cited by 10
Hughes, R., Snook, A. E., & Mueller, A. C. (2022) · Immunotherapy · doi:10.2217/imt-2022-0046 · Cited by 7
Hypoxia, Stem Cells and Cancer Stem Cells
Manian, M., Taherian, M., Nickho, H., Nejad, A. E., & Shaverdi, S. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_3 · Cited by 7
Myeloid Derived Suppressor Cells: Subsets, Expansion, and Role in Cancer Progression
Abastado, J., & Zhi, L. (2012) · InTech eBooks · doi:10.5772/36409 · Cited by 8
Immunometabolism in the Bladder Cancer Microenvironment
Fattahi, M. J., Haghshenas, M. R., & Ghaderi, A. A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220104103905 · Cited by 6
An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
Zhang, T., Gu, Z., Ni, R., Wang, X., Jiang, Q., & Tao, R. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812361 · Cited by 6
αB‐Crystallin regulates expansion of CD11b + Gr‐1 + immature myeloid cells during tumor progression
Dieterich, L. C., Schiller, P., Huang, H., Wawrousek, E. F., Loskog, A., Wanders, A., Moons, L., & Dimberg, A. (2012) · The FASEB Journal · doi:10.1096/fj.12-213017 · Cited by 7
Antitumor effects of targeting myeloid-derived suppressive cells
Zeng, D., Long, H., & Zhu, B. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.52 · Cited by 6
Irradiation immunity interactions
Davis, D. A. S., Atmosukarto, I. I., Garrett, J., Gosling, K. M., Syed, F. M., & Quah, B. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13399 · Cited by 6
Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
Castelli, C., Tazzari, M., Negri, T., Vergani, B., Rivoltini, L., Stacchiotti, S., & Pilotti, S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-237 · Cited by 6
Tissue- and Temporal-Dependent Dynamics of Myeloablation in Response to Gemcitabine Chemotherapy
Kitelinger, L. E., Thim, E. A., Zipkowitz, S., Price, R. J., & Bullock, T. N. J. (2024) · Cells · doi:10.3390/cells13161317 · Cited by 5
MDSCs in Breast Cancer: Metastasis, Lipid Metabolism, and Therapeutics
Kim, U., & Chakrabarti, R. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0838 · Cited by 6
Myeloid metabolism and its role in immunotherapy of cancer
Garlatti, V., Consonni, F. M., Ballerini, G., Incerti, M., Balboni, A., Cassatella, M. A., & Sica, A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012127 · Cited by 6
CAR-neutrophils produced in vivo to treat glioma
Chang, Y., Shao, K., Li, H., Jin, G., Bentley, R. T., McCain, R. R., Crain, C. J., Shen, J., Tan, Y., Liang, P.-Y., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01656-0 · Cited by 12
Khouzam, R. A., Salman, S., Thiery, J., Zaarour, R. F., Vela, V., Limani, P., Janji, B., & Chouaïb, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093873 · Cited by 7
Metabolic adaptations of immunosuppressive cells in cancer: mechanisms and therapeutic targets
Kim, J., Shin, J. M., Um, Y., Yuan, S., & Lim, S. A. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01713-3 · Cited by 11
Azhdarifam, S., Metanat, M., Ghobeishavi, N., Nouroloyouni, S., & Jahanban‐Esfahlan, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119529 · Cited by 5
The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer
Nie, J., Wang, D., & Li, M. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03160-2 · Cited by 6
Tumor-induced Myeloid-derived Suppressor Cells
Ostrand‐Rosenberg, S., Sinha, P., Beury, D. W., Chornoguz, O., & Parker, K. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00028-2 · Cited by 5
[Immune Characteristics of Small Cell Lung Cancer].
Zhu, Y., & Wu, S. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.33 · Cited by 6
The impact of microRNAs on myeloid-derived suppressor cells in cancer
Baghbani, E., Noorolyai, S., Duijf, P. H. G., Silvestris, N., Kolahian, S., Hashemzadeh, S., Baghbanzadeh, A., FallahVazirabad, A., & Baradaran, B. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.04.009 · Cited by 5
Ray, S. K., & Mukherjee, S. (2022) · Current Drug Targets · doi:10.2174/1389450123666220111114649 · Cited by 6
Novel approaches to promote CAR T-cell function in solid tumors
Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5
Proskurina, A. S., Ruzanova, V. S., Ostanin, A. A., Chernykh, E. R., & Bogachev, S. S. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-919 · Cited by 6
Steinberger, K. J., Forget, M. A., Bobko, A. A., Mihalik, N. E., Gencheva, M., Roda, J. M., Cole, S. L., Mo, X. M., Hoblitzell, E. H., Evans, R., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001134 · Cited by 5
A mini-review: photodynamic therapy-induced immune activation
Cai, X., Leung, A. W. N., Lv, L., & Xu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1746961 · Cited by 5
Xu, Q., Liu, H., Song, X., Wuren, T., & Ge, R. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002126 · Cited by 4
Bhardwaj, V., Yang, Z.-Z., Jalali, S., Villasboas, J. C., Mudappathi, R., Wang, J., Mukherjee, P., Paludo, J., Tang, X., Kim, H. J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01173-w · Cited by 9
Wang, Y., Dong, Q., Yuan, M., Hu, J., Lin, P., Yan, Y., Yan, Y., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113892 · Cited by 5
Mahanti, K., Saha, J., Sarkar, D., Pramanik, A., Das, D., Mondal, P., Mahato, M., & Bhattacharyya, S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00199 · Cited by 5
Myeloid-Derived Suppressor Cells in Some Oncohematological Diseases
Ponomarev, А. V. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-1-29-38 · Cited by 4
Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages
Mehrabi, M., Amini, F., & Mehrabi, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693076 · Cited by 4
Ji, J., Zhuang, Y., Lin, Z., Jiang, Y., Wang, W., & Zhang, X. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000518876 · Cited by 3
Cancer immunosurveillance in respiratory diseases
Cubillos‐Zapata, C., Díaz‐García, E., & Rio, F. G. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018021 · Cited by 6
Zakaria, S., Elsebaey, S., Allam, S., Abdo, W., & El‐Sisi, A. E. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230116142606 · Cited by 5
Chen, H., Hao, P.-H., Zhang, F., & Zhang, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114346 · Cited by 5
Unravelling the role of obesity and lipids during tumor progression
Zhao, J., Lee, K., Toh, H. C., Lam, K., & Neo, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163160 · Cited by 5
Li, T.-T., Lin, C., Chiang, M., He, J.-T., Hung, C., & Hsieh, C. (2023) · Cells · doi:10.3390/cells12111507 · Cited by 4
Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours
Bokil, A. A., Børkja, M. L. B., Wolowczyk, C., Lamsal, A., Prestvik, W. S., Nonstad, U., Pettersen, K., Andersen, S. B., Bofin, A. M., Bjørkøy, G., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03136-w · Cited by 5
MDSC expansion during HIV infection: regulators, ART and immune reconstitution
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00272-9 · Cited by 4
C/EBPδ: friend or foe? A novel role for C/EBPδ in metastasis
Pelorosso, F. G., & Balmain, A. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.308 · Cited by 4
Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer
Ostrand‐Rosenberg, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17015-8 · Cited by 4
Immune Landscape of Intrahepatic Cholangiocarcinoma: Evasion and Therapeutic Insights
Porro, N., Spínola-Lasso, E., Marra, F., & Gentilini, A. (2025) · Immuno · doi:10.3390/immuno5030040 · Cited by 4
Bogadi, S., Uddin, M. E., Karri, V. V. S. R., Begum, R., Kader, M. A., Abullais, S. S., Reza, M. S., Alexiou, A. T., & Papadakis, M. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02582-4 · Cited by 4
Soil and Seed: Tumor Microenvironment Nurtures Immunotherapy Resistance and Renewal
Li, Y., Feng, Q., Xia, Y., Liao, L., & Xie, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110547 · Cited by 6
The hypoxic tumor microenvironment: Functional and metabolic reprogramming of key immune populations
Ojaroodi, A. F., Shokravi, S., Eskandarzadeh, S., Ghahremanzadeh, A., Alizadeh, F., Amirikar, F., Mobayen, G., Mahrooghi, D., Lahouty, M., Shamsasenjan, K., et al. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156443 · Cited by 8
The central regulator HIF-1α in digestive system pathologies: inflammation and cancer
Gou, G., Wen, M., Li, G., Shu, F., Wang, F., Liu, Y., Xie, R., & Xu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772110 · Cited by 5
Radiation-induced remodeling of the T cell landscape in head and neck cancer
Memon, A. A., Said, I., Norenberg, E. P., Frei, A. C., Foeckler, J., Sun, F., Dwinell, M. B., Lochhead, R. B., Bruening, J., Akakpo, K. E., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04389-w · Cited by 4
Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment
Wang, Y., Lu, Y., Zhou, J., & Yang, X. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70665 · Cited by 5
Zhang, H., Liu, W., Zhang, Y., 陈舒晨, & Sun, G. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1840613 · Cited by 5
Zhang, B., Tang, Q., Shi, W., Bao, Z., Gao, S., & Pan, C. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2351629 · Cited by 3
Doi, M., Tanaka, H., Ohoto, T., Miura, N., Sakurai, Y., Hatakeyama, H., & Akita, H. (2023) · Small · doi:10.1002/smll.202205131 · Cited by 6
Myeloid‐derived suppressor cells: Are they involved in gestational diabetes mellitus?
Hua, S., Wang, S., Cai, J., Wu, L., & Cao, Y. (2023) · American Journal of Reproductive Immunology · doi:10.1111/aji.13711 · Cited by 3
Nieberle, F., Spoerl, S., Głuszko, A., Taxis, J., Spanier, G., Erber, R., Spoerl, S., Szczepański, M. J., Beckhove, P., Reichert, T. E., et al. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.73 · Cited by 5
Biology of Myeloid-Derived Suppressor Cells
Alicea-Torres, K. M., & Gabrilovich, D. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_10 · Cited by 3
Self-citationThe Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells
Shime, H., Matsumoto, M., & Seya, T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55327-4_3 · Cited by 3
Ming, P. (2014) · Medical Science Monitor · doi:10.12659/msm.891048 · Cited by 3
Modulation of Innate Immunity by Hypoxia
Riboldi, E., & Sica, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801968-9.00004-0 · Cited by 3
Immunology of Cutaneous Tumors and Immunotherapy for Melanoma
Saghazadeh, A., Saghazadeh, M., & Rezaei, N. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_14 · Cited by 3
Ohta, A., & Sitkovsky, M. V. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_14 · Cited by 4
Effects of different hypoxia exposure on myeloid-derived suppressor cells in mice
Xu, Q., Liu, H., Ye, Y., Wuren, T., & Ge, R. (2024) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2024.104932 · Cited by 2
Deciphering hypoxia’s role in hepatocellular carcinoma prognosis with single-cell approaches
Liang, J., Chen, D., & Liang, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03201-y · Cited by 5
Teng, Y., Chen, Y., Xia, X., Zhu, D., Tang, X., Tian, J., Ma, J., Yin, K., & Wang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115303 · Cited by 3
The implied dysregulated RKIP-hypoxia axis in cancer and immune evasion: Clinical implications
McWhorter, R., Chouaïb, S., & Bonavida, B. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101328 · Cited by 2
Yang, J., Li, X., Zhu, X., Li, Z., Chen, X., Huang, R., Yu, M., Han, B., Jiang, T., Zhang, C., et al. (2026) · 癌症:英文版 · doi:10.34133/cancomm.0007 · Cited by 3
APX3330 reverses the immunosuppressive tumor microenvironment during colorectal carcinogenesis
Wang, L., Hang, R., Xiao, H., Li, C., Hu, N., Gao, H. J., Yang, Y., Wang, D., Li, M., Chen, Q., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04176-8 · Cited by 2
Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro
Hidalgo, L., Garcia-Rodriguez, P., Cubillo, I., Zubizarreta, M., Pérez-Martínez, A., & García-Castro, J. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04319-w · Cited by 3
Zhang, H., Sun, M., Zhu, X., Lu, Y., Lan, Z., Yu, B., Wu, X., & Jin, Y. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c24938 · Cited by 4
Zhang, X., Tao, X., Zhang, Y., Gan, G., Lv, J., Zhang, L., & Dong, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785625 · Cited by 7
Li, H., Liu, C., Zhang, B., Zhang, Y., & Liu, Y. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06471-3 · Cited by 3
Yang, B., Liu, S., Liu, B., Ye, T., Ma, X., & Song, T. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02883-3 · Cited by 4
Alban, T. J., Bayık, D., Alvarado, A. G., Kornblum, H. I., & Lathia, J. D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1060-2_13 · Cited by 2
Progress in research on the role played by myeloid‐derived suppressor cells in liver diseases
Sun, Q.-Q., Dai, H., Wang, S., Chen, Y., & Shi, H. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13312 · Cited by 2
Piqueras-Nebot, M., Benet, M., Estors, M., Cremades, A., Juan, Ó., Carretero, J., Galbis, J. M., & Lahoz, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-99877-x · Cited by 2
Tran, R. L., Liang, X., de la Cerda, J., Schuler, F. W., & Pagel, M. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-05930-0 · Cited by 3
Demaria, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00011-7 · Cited by 2
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.